Method of treating and preventing loss of bone mass using 1.alph

Details Method of treating and preventing loss of bone mass using 1.alph Method of treating and preventing loss of bone mass using 1.alph

1993-09-10

1995-04-04

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

514168, 552653, A61K 3159, A61K 31595

Patent

active

054038316

ABSTRACT:
A method for reversing loss of bone mass or bone mineral content in a human being suffering from osteoporosis is disclosed which comprises administering to the human being a daily dosage of at least 2.0 micrograms/day of 1-alpha-hydroxy-Vitamin D.sub.2.

REFERENCES:
patent: 4225596 (1980-09-01), DeLuca et al.
patent: 4508651 (1985-04-01), Baggiolini et al.
patent: 4588716 (1986-05-01), DeLuca et al.
patent: 5104864 (1992-04-01), DeLuca et al.
Lam et al., "1.alpha.-hydroxy Vitamin D.sub.2 : A Potent Synthetic Analog of Vitamin D.sub.2." Science vol. 186, Nr. 4168, 1974, pp. 1038-1040.
Reeve, L. E., et al., "Biological Activity of 1.alpha.-hydroxy Vitamin D.sub.2 in the Rat." Arch. Biochem. Biophys. vol. 186, Nr. 1, Feb. 1978, pp. 164-167.
Sjoden et al., "Effects of 1 OHD.sub.2 on Bone Tissue," Acta. Endocrinol. (Copenh.) vol. 16, NR. 4, Aug. 1984, pp. 564-568.
Sjoden et al., J. Nutr: 114, 2043-2046 (1984).
Sjoden et al., Proc. Soc. Exp. Biol.: Med 178, 432-436 (1985).
Physician's Desk Reference, Edition 43, pp. 1746-1748 (1982).
Tanaka, Y. et al., Endocrinology, 1973; 92: 417-422.
Sorenson, O. H. et al., Clin. Endocrinol, 1977; 7:169S-175S.
Hoika, V. et al., Acta. Med. Scand., 1980; 207:221-224.
Shiraki, M. Endocrinol. Japan, 1985; 32:305-315.
Aloia, J. et al., Amer. J. Med. 1988; 84:401-408.
Brown et al., Lancet, 1:1091-1983 (1984).
Podenphant, J. et al., Acta Med Scand. 1985; 218:329-333.
Canigga et al., Calif Tissue Int, 1986; 38:328-332.
Duda et al., J. Clinic Invest. 1987; 79:1249-1253.
Zerwebb et al., J. Clin. Endocrinol. Metabol., 1985; 60:615-617.
Horst et al., Anal. Biochem., 1981; 116: 189-203.
Horst et al., Biochem. J., 1982; 204:185-189.
Sommerfeldt et al., J. Nutr. 1983; 11:2595-2600.
Brautbar, N. Nephron. 1986; 44:161-166.
Foldes et al., Osteoporosis 1987, C. Christianson et al. (eds.) Osteopress Aps, Copenhagen, pp. 971-973.
Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis, HEW (FDA) 80-3094, pp. 5-6 (1979).
J. A. Kanis et al. Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis. Osteoporosis Int., 1:182-188 (1991).
C. Christiansen et al. Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females. Europ J Clin Invest, 10:273-279 (1980).
J. M. Pouilles et al. Prevention of Post-Menopausal Bone Loss with 1.alpha.-Hydroxy Vitamin D.sub.3, A Three-Year Prospective Study. Clin. Rheumatol. 11, No. 4:492-497 (1992).

Affiliated with

Also associated with

Rating

Method of treating and preventing loss of bone mass using 1.alph does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating and preventing loss of bone mass using 1.alph, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating and preventing loss of bone mass using 1.alph will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2380775